Literature DB >> 32032505

Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains.

Tamta Arakhamia1, Christina E Lee1, Yari Carlomagno2, Duc M Duong3, Sean R Kundinger3, Kevin Wang1, Dewight Williams4, Michael DeTure2, Dennis W Dickson2, Casey N Cook2, Nicholas T Seyfried5, Leonard Petrucelli6, Anthony W P Fitzpatrick7.   

Abstract

Tau aggregation into insoluble filaments is the defining pathological hallmark of tauopathies. However, it is not known what controls the formation and templated seeding of strain-specific structures associated with individual tauopathies. Here, we use cryo-electron microscopy (cryo-EM) to determine the structures of tau filaments from corticobasal degeneration (CBD) human brain tissue. Cryo-EM and mass spectrometry of tau filaments from CBD reveal that this conformer is heavily decorated with posttranslational modifications (PTMs), enabling us to map PTMs directly onto the structures. By comparing the structures and PTMs of tau filaments from CBD and Alzheimer's disease, it is found that ubiquitination of tau can mediate inter-protofilament interfaces. We propose a structure-based model in which cross-talk between PTMs influences tau filament structure, contributing to the structural diversity of tauopathy strains. Our approach establishes a framework for further elucidating the relationship between the structures of polymorphic fibrils, including their PTMs, and neurodegenerative disease.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; acetylation; corticobasal degeneration; cryo-EM; integrated structural biology; posttranslational modifications; tau strains; tauopathy; templated seeding; ubiquitination

Mesh:

Substances:

Year:  2020        PMID: 32032505      PMCID: PMC7491959          DOI: 10.1016/j.cell.2020.01.027

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  71 in total

1.  The acetylation of tau inhibits its function and promotes pathological tau aggregation.

Authors:  Todd J Cohen; Jing L Guo; David E Hurtado; Linda K Kwong; Ian P Mills; John Q Trojanowski; Virginia M Y Lee
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

2.  Inference of macromolecular assemblies from crystalline state.

Authors:  Evgeny Krissinel; Kim Henrick
Journal:  J Mol Biol       Date:  2007-05-13       Impact factor: 5.469

Review 3.  Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau).

Authors:  Dennis W Dickson; Naomi Kouri; Melissa E Murray; Keith A Josephs
Journal:  J Mol Neurosci       Date:  2011-07-01       Impact factor: 3.444

4.  Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species.

Authors:  Chad A Dickey; Mei Yue; Wen-Lang Lin; Dennis W Dickson; Judith H Dunmore; Wing C Lee; Cynthia Zehr; Gemma West; Songsong Cao; Amber M K Clark; Guy A Caldwell; Kim A Caldwell; Christopher Eckman; Cam Patterson; Michael Hutton; Leonard Petrucelli
Journal:  J Neurosci       Date:  2006-06-28       Impact factor: 6.167

5.  Tau binds ATP and induces its aggregation.

Authors:  Mina Farid; Christopher P Corbo; Alejandra Del C Alonso
Journal:  Microsc Res Tech       Date:  2013-11-21       Impact factor: 2.769

Review 6.  Tauopathies as clinicopathological entities.

Authors:  David J Irwin
Journal:  Parkinsonism Relat Disord       Date:  2015-09-08       Impact factor: 4.891

7.  Ballooned neurons in select neurodegenerative diseases contain phosphorylated neurofilament epitopes.

Authors:  D W Dickson; S H Yen; K I Suzuki; P Davies; J H Garcia; A Hirano
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

Review 8.  The amyloid state and its association with protein misfolding diseases.

Authors:  Tuomas P J Knowles; Michele Vendruscolo; Christopher M Dobson
Journal:  Nat Rev Mol Cell Biol       Date:  2014-06       Impact factor: 94.444

9.  Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.

Authors:  Meaghan Morris; Giselle M Knudsen; Sumihiro Maeda; Jonathan C Trinidad; Alexandra Ioanoviciu; Alma L Burlingame; Lennart Mucke
Journal:  Nat Neurosci       Date:  2015-07-20       Impact factor: 24.884

10.  A validated antibody panel for the characterization of tau post-translational modifications.

Authors:  Ebru Ercan; Sameh Eid; Christian Weber; Alexandra Kowalski; Maria Bichmann; Annika Behrendt; Frank Matthes; Sybille Krauss; Peter Reinhardt; Simone Fulle; Dagmar E Ehrnhoefer
Journal:  Mol Neurodegener       Date:  2017-11-21       Impact factor: 14.195

View more
  106 in total

1.  Hydration and Dynamics of Full-Length Tau Amyloid Fibrils Investigated by Solid-State Nuclear Magnetic Resonance.

Authors:  Aurelio J Dregni; Pu Duan; Mei Hong
Journal:  Biochemistry       Date:  2020-06-05       Impact factor: 3.162

2.  Posttranslational modifications define course of prion strain adaptation and disease phenotype.

Authors:  Natallia Makarava; Jennifer Chen-Yu Chang; Kara Molesworth; Ilia V Baskakov
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

3.  The Two Cysteines of Tau Protein Are Functionally Distinct and Contribute Differentially to Its Pathogenicity in Vivo.

Authors:  Engie Prifti; Eleni N Tsakiri; Ergina Vourkou; George Stamatakis; Martina Samiotaki; Katerina Papanikolopoulou
Journal:  J Neurosci       Date:  2020-12-17       Impact factor: 6.167

Review 4.  Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Authors:  Wenyan Zhang; Shuoyan Xu; Hongmei Yu; Xuena Li; Zhuangzhuang Jin; Yaming Li; Zhiyi He
Journal:  Ann Nucl Med       Date:  2021-01-18       Impact factor: 2.668

Review 5.  Mitochondria-ER Tethering in Neurodegenerative Diseases.

Authors:  Reza Raeisossadati; Merari F R Ferrari
Journal:  Cell Mol Neurobiol       Date:  2020-11-16       Impact factor: 5.046

6.  Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo.

Authors:  Sarah A Weitzman; Sneha Narasimhan; Zhuohao He; Lakshmi Changolkar; Jennifer D McBride; Bin Zhang; Gerard D Schellenberg; John Q Trojanowski; Virginia M Y Lee
Journal:  J Neuropathol Exp Neurol       Date:  2020-09-01       Impact factor: 3.685

7.  Asparagine residue 368 is involved in Alzheimer's disease tau strain-specific aggregation.

Authors:  Shotaro Shimonaka; Shin-Ei Matsumoto; Montasir Elahi; Koichi Ishiguro; Masato Hasegawa; Nobutaka Hattori; Yumiko Motoi
Journal:  J Biol Chem       Date:  2020-08-05       Impact factor: 5.157

8.  Atomic Force Microscopy Imaging and Nanomechanical Properties of Six Tau Isoform Assemblies.

Authors:  Ali Makky; Luc Bousset; Karine Madiona; Ronald Melki
Journal:  Biophys J       Date:  2020-11-18       Impact factor: 4.033

9.  Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.

Authors:  Simon Dujardin; Caitlin Commins; Aurelien Lathuiliere; Pieter Beerepoot; Analiese R Fernandes; Tarun V Kamath; Mark B De Los Santos; Naomi Klickstein; Diana L Corjuc; Bianca T Corjuc; Patrick M Dooley; Arthur Viode; Derek H Oakley; Benjamin D Moore; Kristina Mullin; Dinorah Jean-Gilles; Ryan Clark; Kevin Atchison; Renee Moore; Lori B Chibnik; Rudolph E Tanzi; Matthew P Frosch; Alberto Serrano-Pozo; Fiona Elwood; Judith A Steen; Matthew E Kennedy; Bradley T Hyman
Journal:  Nat Med       Date:  2020-06-22       Impact factor: 53.440

Review 10.  Cell-to-Cell Transmission of Tau and α-Synuclein.

Authors:  Norihito Uemura; Maiko T Uemura; Kelvin C Luk; Virginia M-Y Lee; John Q Trojanowski
Journal:  Trends Mol Med       Date:  2020-05-01       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.